(Q40617686)

22 September 2017

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment (English)

1 reference

22 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Henri Merdjan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antoine Tarral

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jianguo Li

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

12 July 2016

1 reference

The Journal of Clinical Pharmacology

22 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

211-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa

10 June 2020

cites work

1 reference

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

21 January 2018

1 reference

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases

21 January 2018

1 reference

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

21 January 2018

1 reference

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -Lactamases

21 January 2018

1 reference

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud

21 January 2018

1 reference

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

21 January 2018

1 reference

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

21 January 2018

1 reference

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-dir

21 January 2018

1 reference

Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

21 January 2018

1 reference

Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies

21 January 2018

1 reference

Pharmacokinetics of ceftazidime in patients with renal insufficiency

21 January 2018

1 reference

Pharmacokinetics of ceftazidime in normal and uremic subjects

21 January 2018

1 reference

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402250%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference